With the advances in hepatocellular carcinoma (HCC) treatment, the lung metastasis of HCC is becoming increasingly important. In treating the lung metastasis of HCC, a multidisciplinary approach can lead to better results than systemic chemotherapy alone. Here, we report on a patient who presented with pulmonary masses, while the HCC was being controlled in the abdominal cavity. The presence of nontuberculous mycobacteria was identified during the diagnosis of the pulmonary masses. The pulmonary metastases of HCC were treated with a combination of angiotherapy, radiation therapy, and radiofrequency ablation. The patient showed a satisfactory progress with this multidisciplinary localized treatment. We report the clinical progress and review the recent literature regarding the treatment of pulmonary metastasis without intrahepatic HCC herein.
IntroductIon
Hepatocellular carcinoma (HCC) is the seventh most common malignant neoplasm in the world, 1 and it has a high incidence in Korea. 2 The lungs are the most common site of the extrahepatic metastasis of HCC. In patients who develop pulmonary metastasis without intrahepatic HCC, surgery could result in successful outcomes. 3 However, most patients with pulmonary metastases may not be operable, because of the location of the lung lesion, surgical technical problems or poor pulmonary function. In this situation, a multidisciplinary approach can lead to better results. 4, 5 We report a patient with pulmonary metastases without intrahepatic HCC, who was successfully treated with the combination of angiotherapy, radiotherapy, and radiofrequency ablation.
cASE rEPort
Clinical findings
A 61-year-old man visited the emergency room with massive hemoptysis and cough. The patient had been diagnosed and treated for tuberculosis in his twenties. The patient was currently taking entecavir for hepatitis B and liver cirrhosis.
The patient had been diagnosed with HCC 6 years ago. Initially, the patient had a 10-cm single mass. After five months, the patient revisited the emergency room with massive hemoptysis and cough. In the emergency room, his blood pressure was 130/70 mmHg, body temperature was 36.5°C, pulse rate was 102 beats/min, and respiration rate was 25 breaths/min. There was no cardiac murmur.
There was a coarse crackle in the right lung field. There were no other unusual findings on abdominal, skin, and joints examinations.
In the complete blood count test, the white blood cell 
Image findings
The CECT performed in the emergency room showed that there was no active bleeding, but ground-glass opacity was found, which was caused by the aspirated blood. The previously identified lung masses had increased in size. The LUL mass increased from 3.9 cm to 4.4 cm, and the RLL mass increased from 1.1 cm to 1.6 cm (Fig. 2 ).
Diagnosis and treatment progress
It was estimated that the massive hemoptysis had been caused by dilated vessels surrounding the lung masses. To plan the treatment of the lung masses, we concluded that On follow-up CECT, the size of the LUL mass was reduced, and the size of the RLL mass remained the same (Fig.   4A ). The patient received radiotherapy for the LUL mass.
The total cumulative dose of 3,500 cGy radiation was administered in seven fractions for the LUL mass. On follow-up CECT, there was no radiologic change in the LUL mass, but the size of the RLL mass increased (Fig. 4B) . The patient underwent RFA for the RLL mass.
Currently, there is no viable portion of the RLL mass on follow-up CECT (Fig. 5) . The level of the tumor marker PIVKA-II reduced to 27 mAU/mL, which is within its normal range.
dIScuSSIon
The lungs are the most frequent site for the HCC metastasis. Sorafenib is usually chosen as the treatment for an intraabdominal HCC lesions with pulmonary metastasis.
However, few patients achieve a successful response with molecular targeted therapy (MTT), because of tumor heterogeneity and complex cell signal transduction. 6 In cases of isolated pulmonary metastasis, without an intraabdominal HCC lesion, an active multidisciplinary approach can produce good results.
This case is meaningful in suggesting two lessons. First, physicians should keep in mind that a pulmonary lesion and lymph node enlargement could have different pathologies.
Second, a combination of localized therapies should be considered for the treatment of isolated pulmonary metastases.
In this case, the presence of NTM was confirmed in the lymph nodes, and HCC was confirmed in the pulmonary nodules. There was histologic discrepancy between the pulmonary lesion and the mediastinal lymph node. Independently of the pulmonary lesion, mediastinal lymph node enlargement can also be observed in double primary cancer or benign diseases, such as tuberculosis, NTM infection, and sarcoidosis. 7 The prevalence of NTM infection is increasing in Korea. 8 In this context, the possibility of differences between pulmonary lesion and mediastinal lymph node pathologies should be considered.
The standard treatment of choice for isolated pulmonary metastases of HCC without intraabdominal lesions is surgical resection. 3 However, surgery should be performed in selected patients, because only few patients could experience benefits, such as prolonged survival time following surgery.
Indications for surgical resection include controlled intraabdominal HCC, no metastases to organs other than the lungs, complete resection of metastatic lesions, and sufficient pulmonary function for surgery. 9 As the proportion of patients meeting these conditions is small, most patients cannot undergo surgical resection.
In such cases, MTT could be considered. rected delivery of vaso-occlusive materials directly into the arteries supplying the tumor.
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On follow-up CECT, the contrast medium accumulated in the medial side of the LUL mass, which required further treatment. RFA and radiation therapy could both be considered for localized treatment. 13 Radiation therapy was chosen based on the location of the metastatic lesion, because the lesion size was large and the location of the mass was difficult to reach with RFA.
RFA is a treatment mainly performed as a localized treatment for intraabdominal HCC, including adrenal metastasis.
Recently, RFA has also been performed as a localized treatment for pulmonary metastasis of HCC. 13, 14 RFA can be used in cases wherein the size of the mass is small and the mass does not invade mediastinal structures. In this case, the RLL mass was suitable for RFA.
Currently, the patient status is stable. Further treatment will be considered for the LUL mass if either the uptake in positron emission tomography-computed tomography or PIVKA II level increases. This case is clinically relevant because three localized therapies were applied (radiotherapy, RFA, and angiotherapy) and the patient achieved satisfactory outcomes.
